Adrian Bot

16.2k total citations · 1 hit paper
132 papers, 4.3k citations indexed

About

Adrian Bot is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Adrian Bot has authored 132 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Immunology, 74 papers in Oncology and 21 papers in Molecular Biology. Recurrent topics in Adrian Bot's work include CAR-T cell therapy research (67 papers), Immunotherapy and Immune Responses (44 papers) and Immune Cell Function and Interaction (25 papers). Adrian Bot is often cited by papers focused on CAR-T cell therapy research (67 papers), Immunotherapy and Immune Responses (44 papers) and Immune Cell Function and Interaction (25 papers). Adrian Bot collaborates with scholars based in United States, Switzerland and France. Adrian Bot's co-authors include Simona Bot, John M. Rossi, Constantin A. Bona, Daniel J. Smıth, Allen Xue, Sattva S. Neelapu, William Y. Go, Frederick L. Locke, Armin Ghobadi and James N. Kochenderfer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Adrian Bot

129 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

2017 463 citations Frederick L. Locke, Sattva S. Neelapu et al. profile →

Peers

Countries citing papers authored by Adrian Bot

Since Specialization

Citations

This map shows the geographic impact of Adrian Bot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adrian Bot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adrian Bot more than expected).

Fields of papers citing papers by Adrian Bot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adrian Bot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adrian Bot. The network helps show where Adrian Bot may publish in the future.

Co-authorship network of co-authors of Adrian Bot

This figure shows the co-authorship network connecting the top 25 collaborators of Adrian Bot. A scholar is included among the top collaborators of Adrian Bot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adrian Bot. Adrian Bot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation 2024 ·Proceedings of the National Academy of Sciences ·Caitlin M. Tilsed, (unknown), Tyler E. Papp, (unknown), Kenji Kimura, Estela Noguera-Ortega, John Scholler, (unknown), Haig Aghajanian, Adrian Bot, Barbara L. Mui, Ying K. Tam, Drew Weissman, Carl H. June, Steven Μ. Albelda, Hamideh Parhiz	24
2	Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7) 2023 ·Blood Cancer Discovery ·Simone Filosto, Saran Vardhanabhuti, Miguel Canales, Xavier Poiré, Lazaros J. Lekakis, Sven de Vos, Craig A. Portell, (unknown), (unknown), Marco Schupp, Soumya Poddar, (unknown), Carmen M. Warren, Ethan G. Aguilar, Justin A. Budka, (unknown), Justin Chou, Adrian Bot, Rhine R. Shen, Jason R. Westin	18
3	Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses 2022 ·Journal of Clinical Investigation ·Gabrielle Romain, Paolo Strati, Ali Rezvan, Mohsen Fathi, Irfan Bandey, (unknown), Darren Heeke, Ivan Liadi, Mario L. Marques‐Piubelli, Luisa M. Solis, Ankit Mahendra, Francisco Vega, Laurence J.N. Cooper, Harjeet Singh, Mike Mattie, Adrian Bot, Sattva S. Neelapu, Navin Varadarajan	36
4	A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy 2021 ·Cancer Discovery ·Ranjan Upadhyay, Jonathan Boiarsky, (unknown), Judit Svensson‐Arvelund, Matthew Lin, Aleksandra Wroblewska, Sherry Bhalla, Nathalie Scholler, Adrian Bot, John M. Rossi, Norah Sadek, Samir Parekh, Alessandro Laganà, Alessia Baccarini, Miriam Mérad, Brian D. Brown, Joshua Brody	125
5	A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1 2016 ·Blood ·Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Tanya Siddiqi, Caron A. Jacobson, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Alex F. Herrera, Ann S. LaCasce, Adrian Bot, John M. Rossi, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go	23
6	ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL) 2016 ·Annals of Oncology ·Bijal Shah, Januario E. Castro, Nicola Gökbuget, Marie José Kersten, (unknown), William G. Wierda, Gary J. Schiller, Adrian Bot, John M. Rossi, Yizhou Jiang, Lynn Navale, (unknown), Jeff Aycock, Jeff Wiezorek, Rajul K. Jain	4
7	Intra–Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial 2011 ·Clinical Cancer Research ·Antoni Ribas, Jeffrey S. Weber, Bartosz Chmielowski, Begonya Comin-Anduix, (unknown), Michael Douek, Nagesh Ragavendra, Steve Raman, Elizabeth Seja, (unknown), (unknown), David C. Diamond, Zhiyong Qiu, (unknown), Adrian Bot	60
8	Lymph Node–Targeted Immunotherapy Mediates Potent Immunity Resulting in Regression of Isolated or Metastatic Human Papillomavirus–Transformed Tumors 2009 ·Clinical Cancer Research ·Kevin M. Smith, (unknown), Victor Tam, Robb R. Pagarigan, (unknown), (unknown), (unknown), Mayra A. Carrillo, (unknown), Uriel M. Malyankar, (unknown), Diane M. Da Silva, Thomas M. Kündig, W. Martin Kast, Zhiyong Qiu, Adrian Bot	28
9	Abstract #724: A phase 1 clinical trial of immune response and safety of an active immunotherapy regimen co-targeting PRAME and PSMA antigens in subjects with advanced solid malignancies 2009 ·Cancer Research ·(unknown), Nicholas J. Vogelzang, Lee D. Cranmer, Marc S. Ernstoff, Jeffrey S. Weber, John L. Marshall, (unknown), (unknown), Adrian Bot	1
10	Immunologic Control of Tumors by In Vivo Fcγ Receptor-Targeted Antigen Loading in Conjunction with Double-Stranded RNA-Mediated Immune Modulation 2006 ·The Journal of Immunology ·Adrian Bot, Daniel J. Smıth, (unknown), Simona Bot, Constantin A. Bona, Habib Zaghouani	9
11	Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination 2002 ·Journal of Clinical Investigation ·Lilin Wang, Daniel J. Smıth, Simona Bot, Luis Dellamary, (unknown), Adrian Bot	61
12	Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination 2002 ·Journal of Clinical Investigation ·Lilin Wang, (unknown), Simona Bot, Luis Dellamary, (unknown), Adrian Bot	6
13	Plasmid Vaccination with Insulin B Chain Prevents Autoimmune Diabetes in Nonobese Diabetic Mice 2001 ·The Journal of Immunology ·Adrian Bot, Daniel J. Smıth, Simona Bot, Anna C. Hughes, Tom Wolfe, Lilin Wang, C. G. Woods, Matthias von Herrath	76
14	Local IL-4 Expression in the Lung Reduces Pulmonary Influenza-Virus-Specific Secondary Cytotoxic T Cell Responses 2000 ·Virology ·Adrian Bot, Andreas Holz, Urs Christen, Tom Wolfe, (unknown), Richard A. Flavell, Matthias von Herrath	36
15	Autoreactive CD4+ T Cells Protect from Autoimmune Diabetes via Bystander Suppression Using the IL-4/Stat6 Pathway 1999 ·Immunity ·Dirk Homann, Andreas Holz, Adrian Bot, Bryan Coon, Tom Wolfe, Jacob Petersen, Thomas Dyrberg, Michael J. Grusby, Matthias G. von Herrath	159
16	Induction of Antibody Response by DNA Immunization of Newborn Baboons Against Influenza Virus 1999 ·Viral Immunology ·Adrian Bot, Michael H. Shearer, Simona Bot, C. G. Woods, (unknown), (unknown), Sofía Casares, Constantin A. Bona	14
17	Plasmid Expressing the Influenza HA Gene Protects Old Mice from Lethal Challenge with Influenza Virus* 1999 ·Viral Immunology ·Dorel L. Radu, (unknown), Adrian Bot, M E Weksler, C Bona	2
18	Protective Cellular Immunity Against Influenza VirusInduced by Plasmid Inoculation of Newborn Mice 1997 ·Journal of Immunology Research ·Adrian Bot, Simona Bot, Adolfo Garcı́a-Sastre, Constantin A. Bona	24
19	Protective Immunity Elicited by Vaccination with DNA Encoding for a B Cell and a T Cell Epitope of the A/PR/8/34 Influenza Virus 1997 ·Viral Immunology ·Sofía Casares, Teodor-Doru Brumeanu, Adrian Bot, Constantin A. Bona	17
20	DNA Immunization of Newborn Mice with a Plasmid-Expressing Nucleoprotein of Influenza Virus 1996 ·Viral Immunology ·Adrian Bot, Simona Bot, Adolfo Garcı́a-Sastre, Constantin A. Bona	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact